Pharma-webinars
JM pharma webinars
Access our free webinars below, offering valuable insight for research chemists and process development scientists in the pharmaceutical and fine chemical industries.
All access webinars
Multi-component pharmaceutical crystals: From solid form selection to controlled crystallisation
Date: May 2021
Length: 49 minutes
A webinar in collaboration with Technobis Crystallization Systems, presented by JM Scientist Dr Ruth Lunt.
Identifying and choosing the best solid form of an API is crucial in a drug’s development. Therefore, it is always best to conduct a thorough search to identify as many solid forms of the API as possible (polymorphs, salts and cocrystals) to allow the selection of the form with the most desired physical and chemical properties as well as for generation of IP. Once the desired form has been chosen and the API progresses through the development pipeline, the design of a robust and scalable crystallization must be undertaken.
However, as crystallization is not only governed by thermodynamics but also heavily influenced by kinetics, unexpected issues can arise during process scale-up, such as the appearance of previously unseen and undesirable solid forms, the formation of transient polymorphs, and or the phenomena of oiling out. These latter phenomena are often too short-lived to be observed at lab scale but can become process-limiting on a multi-kilogram scale. However, with the arrival of high-resolution process analytical technology (PAT), such phenomena can be observed at a reduced scale. The use of PAT, modelling and design of experiment studies, coupled with expert understanding of the solid form landscape, means that crystallization development can be driven by a Quality by Design (QBD) approach to give a scalable, robust process yielding the desired outcome at an early stage of development.
How CESS technology stacks up against the competition: the smaller, the better!
Date: April 2021
Length: 1 hour
Poor bioavailability and low efficacy are amongst the most common reasons for drug failure. To address this, various particle engineering techniques have received attention for their ability to improve the solubility and bioavailability of drug compounds. Nanoform’s proprietary CESS® technology is one such technique. Johnson Matthey recently collaborated with Nanoform to evaluate CESS compared with other current approaches, including spray-dried amorphous dispersion, hot-melt extrusion, salt, cocrystal, milled and micron-sized active pharmaceutical ingredients.
Senior Scientist, Claire Wombwell, joined Nanoform’s Chief Technology Officer, Niklas Sandler, to discuss the science behind CESS technology and how it can be leveraged to produce nanoparticles that improve the solubility and bioavailability of drug substances.
This webinar was hosted by The Namomed Zone. You'll need to register your details to gain access to the recorded webinar and slides:
Crystallisation in the salt-cocrystal continuum: a tale of two morphologies
Date: August 2020
Length: 1 hour and 15 mins
Crystallisation design is a critical step in the development of many APIs. Optimisation of this process so that it is both scalable and robust can be a time-consuming, labour-intensive process not guaranteed to obtain desirable results. As crystallisation is governed by kinetics as well as thermodynamics, alterations in heat and mass transfer during process scale-up can lead to the appearance of previously unseen and undesirable phenomena on scale. The formation of transient polymorphs and oil-to-crystal transformations which are often short-lived so as to be difficult to observe at lab scale, can become process-limiting on multi kilogram scale. The advent of high-resolution process analytical technology means that such phenomena can be observed at reduced scale. In this presentation, we describe a rational design for the crystallisation of a metastable cocrystal using both modelling and a range of in-situ measurements to minimise experimental burden. A Dynochem® model is developed which describes the crystallisation process and is used to control litre-scale processes from milligram-scale solubility measurements. In process measurements of solution concentration, particle size, particle morphology and crystal form are then used to inform and validate the model. For this, the BlazeMetrics 900 probe is used to identify process changes and guide circumvention of unwanted phenomena. The crystallisation of the metastable cocrystal is successfully scaled-up to validate the model and an accurate prediction of the particle size distribution by the model is realised.
This webinar was hosted by Scientific Update and presented by JM's Dr Joe Harris.
Understanding solid form and crystallisation
Date: June 2020
Length: 56 mins
Choosing the ideal solid form is a crucial point in the life cycle of a molecule. Therefore, it is always best to conduct a thorough search to identify as many forms (polymorphs, salts and cocrystals) as possible to allow you to select the one with the preferred physical/chemical properties and for IP. However, limited material can make this challenging. A well-designed screen, including multiple crystallisation techniques with a diverse set of solvents, can be carried out with little material prioritising analytical techniques to identify solid forms of interest. Furthermore, as a solid form progresses through development, unexpected issues can arise. New forms, oiling out, change in impurity profiles caused by changes in scale, can result in the scrapping of batches, extra production steps or the reset of a molecule potentially costing millions. To minimise risk, crystallisation development driven by Quality by Design (QBD) should be undertaken as soon as possible. Using PAT tools, modelling, design of experiment studies coupled with expert understanding of the solid form and solubility landscape, a scalable, robust process that will give the desired outcome can be built and developed at an early stage of development.
This webinar was presented by Dr Thomas Kendall from Johnson Matthey.
Why new catalysts?
Date: May 2020
Length: 46 mins
Catalysis has been, for a long time, an established tool in the fine chemicals industry. Yet, application scope, catalysts performance, process understanding as well as our expectations are continually evolving. It is worth examining once again the answers to some basic questions: Why catalysis? Why new catalysts? Which new catalysts? Here, we briefly overviewed the rationale for sustainability, economics, technical complementarity of the homogeneous, heterogeneous and biocatalytic technologies offered by Johnson Matthey.
This webinar was presented by Dr Antonio Zanotti-Gerosa and Dr Danny Mortimer from Johnson Matthey.
The coming of age of homogeneous ester hydrogenation
Date: Jan 2020
Length: 48 mins
Homogeneous ester hydrogenation has evolved into an efficient and cost-effective transformation and provides greener access to primary alcohols, important targets in pharmaceutical and flavour and fragrances chemistry. This webinar provides a deeper understanding of the application of the technology.
This webinar is presented by Dr Antonio Zanotti-Gerosa from Johnson Matthey.
